Through the detection of obstructive sleep apnea hypopnea syndrome patients, type2diabetic patients, OSAHS with T2DM patients, healthy control group, we explore its role in the pathogenesis of patients with OSAHS with T2DM.2. Analysis plasma of apelin-12levels of CPAP therapy of the OSAHS its merger with T2DM.
All selected objects are given full-night polysomnography monitoring 7 hours. With the diagnostic criteria of OSAHS and T2DM, were divided into28cases of OSAHS group (O group), OSAHS with T2DM group (referred to as the OD group)28cases, simply the T2DM group (DM group)28cases, choose another28cases normal control group (group N).
All selected plasma of apelin-12levels measured by ELISA.2.20cases OSAHS and OSAHS with T2DM patients nCPAP curing after30days, and review of the PSG, fasting blood glucose (FBG), to observe plasma concentration of apelin-12the changes.
O group, DM group and the OD group, the plasma of apelin-12were higher increased than those in group N (P<0.05), level of the OD group is the highest.
The OD group compared with the O group and DM group, the plasma level of apelin-12were significant differences (P<0.05); O group compared with the DM group, the plasma level differences of apelin-12is not significantly.2. The plasma of apelin-12levels O group and the OD group are decreased after nCPAP therapy than before (P<0.05).3.
Plasma of apelin-12levels and AHI, BMI, of FBG, NC have a positive correlation (P<0.05); Plasma of apelin-12levels and LSaO2MSaO2have a negative correlation (P<0.05).Conclusion:1. The plasma of apelin-12can be used as predictors of OSAHS with T2DM patients.2. nCPAP therapy can improve OSAHS the patient’s plasma of apelin-12levels and blood sugar levels. It can also delay the chance of occurrence of type2diabetes development in the OSAHS patient group.